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Peripheral blood epi-signature of Claes-
Jensen syndrome enables sensitive and
specific identification of patients and
healthy carriers with pathogenic mutations
in KDM5C
Laila C. Schenkel1,2†, Erfan Aref-Eshghi1,2†, Cindy Skinner3, Peter Ainsworth1,2, Hanxin Lin1,2, Guillaume Paré4,
David I. Rodenhiser5, Charles Schwartz3 and Bekim Sadikovic1,2,6*
Abstract
Background: Claes-Jensen syndrome is an X-linked inherited intellectual disability caused by mutations in the
KDM5C gene. Kdm5c is a histone lysine demethylase involved in histone modifications and chromatin remodeling.
Males with hemizygous mutations in KDM5C present with intellectual disability and facial dysmorphism, while most
heterozygous female carriers are asymptomatic. We hypothesized that loss of Kdm5c function may influence other
components of the epigenomic machinery including DNA methylation in affected patients.
Results: Genome-wide DNA methylation analysis of 7 male patients affected with Claes-Jensen syndrome and 56
age- and sex-matched controls identified a specific DNA methylation defect (epi-signature) in the peripheral blood
of these patients, including 1769 individual CpGs and 9 genomic regions. Six healthy female carriers showed less
pronounced but distinctive changes in the same regions enabling their differentiation from both patients and controls.
Highly specific computational model using the most significant methylation changes demonstrated 100% accuracy
in differentiating patients, carriers, and controls in the training cohort, which was confirmed on a separate cohort of
patients and carriers. The 100% specificity of this unique epi-signature was further confirmed on additional 500
unaffected controls and 600 patients with intellectual disability and developmental delay, including other patient
cohorts with previously described epi-signatures.
Conclusion: Peripheral blood epi-signature in Claes-Jensen syndrome can be used for molecular diagnosis and
carrier identification and assist with interpretation of genetic variants of unknown clinical significance in the
KDM5C gene.
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Background
DNA methylation and histone modifications are the
most widely studied epigenetic mechanisms, involved in
the control of gene expression and maintenance of gen-
omic stability. Post-translational modifications of histone
proteins are coordinated by a variety of enzymes that
catalyze histone methylation, demethylation, acetylation,
deacetylation, phosphorylation, ubiquitination, SUMOy-
lation, and ADP-ribosylation [1]. Mutations in the genes
involved in the modification of histones cause a broad
spectrum of Mendelian disorders [2]. Among these are
mutations in the X-linked gene KDM5C, which encodes
the histone H3 lysine 4 (H3K4) demethylase protein and
causes Claes-Jensen syndrome [2].
The clinical manifestations in affected males carrying
hemizygous KDM5C mutations include intellectual dis-
ability, impairments in adaptive behavior, slowly progres-
sive spastic paraplegia, seizures, and facial dysmorphism
[3, 4]. KDM5C is among the genes that escape X-
chromosome inactivation; therefore, female mutation
carriers usually remain unaffected but can demonstrate
mild learning deficits [5].
Recent studies have suggested a bidirectional relation-
ship between DNA methylation and histone modifica-
tion which regulates locus-specific gene activity [6]. For
instance, the DNA methyltransferase Dnmt3b1 select-
ively binds to the bodies of transcribed genes, leading to
their de novo methylation, and its recruitment requires
co-transcriptional deposition of histone H3 trimethyla-
tion at lysine 36 [7]. These findings have encouraged
global efforts to elucidate the specific underlying mo-
lecular mechanisms that may be altered in epigenetic
syndromes and to identify epi-signatures that can be
used for diagnosis, particularly in those patients whose
clinical manifestations are associated with a phenotypic
spectrum shared across more than one syndrome, a situ-
ation where a specific clinical diagnosis is difficult to
make.
Using a genome-wide DNA methylation analysis, we
and others have identified specific DNA methylation
epi-signatures in the peripheral blood of patients with
a number of genetic diseases that result from the
disruption of epigenomic machinery, including alpha-
thalassemia/mental retardation X-linked (ATRX) syn-
drome [8], Floating-Harbor syndrome [9], DNA methyl-
transferase 1 (DNMT1)-associated autosomal dominant
cerebellar ataxia, deafness, and narcolepsy syndrome
[10], along with Kabuki [11, 12] and Sotos syndromes
[13]. These epi-signatures from peripheral blood spec-
imens can be used to accurately identify patients with
these conditions, to assist with the interpretation of
genetic variants of unknown significance in related
genes, and ultimately, to be used as part of the rou-
tine molecular screening protocols in patients with a
broad range of developmental delay and intellectual dis-
ability disorders [14, 15].
In this report, we used a high-resolution genome-wide
methylation microarray analysis to describe a specific
methylation profile in peripheral blood samples of a co-
hort of affected males with loss-of-function KDM5C
mutations and a similar but less pronounced methyla-
tion change in healthy female carriers. We demonstrate
that the DNA methylation signature of Claes-Jensen syn-
drome has the potential to be used as a diagnostic tool
for detection of both patients and healthy carriers with
KDM5C mutations. We further show that this epi-
signature is highly specific to KDM5C mutations, but
not to the broad range of other Mendelian diseases
resulting from the disruption of genes in the epigenomic
machinery or other forms of developmental delay and
intellectual disabilities (DD/ID).
Methods
Study cohort
Peripheral blood samples from patients referred for gen-
etic testing at the Greenwood Genetic Center were col-
lected for methylation study. All patients were screened
for mutations in the KDM5C and variants assessed ac-
cording to the American College of Medical Genetics
Guidelines for interpretation of genomic sequence vari-
ants [16]. The study included ten male patients affected
with Claes-Jensen syndrome and eight healthy females
carrying pathogenic mutations in KDM5C. All male sub-
jects were clinically confirmed to be affected by the Claes-
Jensen syndrome. The age of the patients was recorded at
the time of blood draw. The mutation status and demo-
graphics of all of the patients are shown in Table 1. These
patients and carriers are members of three unrelated fam-
ilies for whom comprehensive clinical, molecular, and mu-
tation assessments have been previously reported by Abidi
et al. [17]. Controls were selected from our lab reference
cohort of individuals with no known aberrant epigenomic
change, including examination for imprinting defects,
abnormal methylation pattern associated with other devel-
opmental syndromes, and representation of outlier pro-
files in principle component analysis. This reference
cohort includes individuals that were previously selected
from a larger cohort of about 1000 individuals across the
broad range of age, sex, and ethnicity distribution.
Methylation array and quality assessment
Genomic DNA was extracted from peripheral blood
using standard techniques. Following bisulfite conver-
sion, DNA methylation analysis was performed using the
Illumina HumanMethylation450 bead chip (San Diego,
CA), according to the manufacturer’s protocol at the
Genetic and Molecular Epidemiology Laboratory at
McMaster University and the London Health Sciences
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Molecular Genetic Laboratory. This array covers above
485,000 human genomic methylation CpG sites, including
99% of RefSeq genes and 96% of CpG islands. Methylated
and unmethylated intensity data were generated as idat
files and imported into R 3.4.0 for analysis. Normalization
was performed using Illumina normalization method with
background correction using minfi package [18]. Probes
with detection p value > 0.01 were excluded from the
downstream analysis. For further quality improvement,
probes located on chromosomes X and Y, probes known
to contain SNPs at the CpG interrogation or the single
nucleotide extension, and probes known to cross-react
with sex chromosomes were removed. As well, the sam-
ples representing discordance between the predicted
and labeled sex were not used in the analysis. All of the
samples were examined for genome-wide methylation
density, and those deviating from the bimodal distribu-
tion were excluded. The methylation analysis of all of
the controls in this study was performed in the same fa-
cility as patients, and the same data processing pipeline
was used for all of them. A factor analysis using
principle component analysis was performed to rule
out the possibility of a batch effect or other sources of
variability.
Selection of discovery/training and testing cohorts and
controls
The identification of epi-signature was performed using
a randomly selected 75% subset of the male patients
(discovery/training set) using caTools package. The
remaining male patients were used as a testing cohort to
assess the performance of the classification model devel-
oped later in the study. Female carriers were divided into
a training and testing cohort according to the same rule
as affected males, but were only used for training and
validating the classification model. For the patients in
the discovery cohort (75% of affected males), a sex- and
age-matched control group was selected from the reference
control group using MatchIt package. This matched
control group was used in both identifications of the
epi-signature and training of the classification model
(Table 1, Fig. 1).
Table 1 Clinical and molecular characteristics of male patients and female mutation carriers referred for methylation study
Sample ID Sex Age (years) Disease status Mutation Cohort
3694a M 28 Patient c.4439_4440delAG; p.R1481GfsX9 Discovery/training
3695a M 26 Patient c.4439_4440delAG; p.R1481GfsX9 Discovery/training
3696a F 51 Carrier c.4439_4440delAG; p.R1481GfsX9 Training
12551D F 55 Carrier c.229G>A; p.A77T Training
cms6013 M 37 Patient c.229G>A; p.A77T Testing
cms13123A F 66 Carrier c.229G>A; p.A77T Testing
cms13755 M 13 Patient c.229G>A; p.A77T Discovery/training
cms13756 F 17 Carrier c.229G>A; p.A77T Testing
cms13757 F 39 Carrier c.229G>A; p.A77T Training
cms1179 F 54 Carrier c.1510G>A; p.V504M Training
cms1180 M 30 Patient c.1510G>A; p.V504M Discovery/training
cms1181 M 26 Patient c.1510G>A; p.V504M Testing
cms1224 F 54 Carrier c.1510G>A; p.V504M Training
cms1242 M 8 Patient c.1510G>A; p.V504M Discovery/training
cms1243 F 31 Carrier c.1510G>A; p.V504M Training
cms13185 M 2 Patient c.1439C>T; p.P480L Discovery/training
cms13186 M 6 Patient c.1439C>T; p.P480L Testing
cms4919B M 42 Patient c.1583+5G>A; p.E468GfsX2 Discovery/training
fs frameshift
Fig. 1 Schematic description of the study cohort
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Identification of the epi-signature
The methylation levels for each probe were measured as
beta value, calculated from the ratio of the methylated
signals vs. the sum of unmethylated and methylated sig-
nals, ranging between 0 (no methylation) and 1 (full
methylation). This value was used for biological inter-
pretation and visualization. For the purpose of statistical
analysis, wherever a normal distribution was required,
beta values were transformed to M values using the fol-
lowing logit equation: log2(beta/(1 − beta)). To identify
the differentially methylated probes, a linear regression
modeling using the limma package was used [19]. The
analysis was adjusted for blood cell type compositions
predicted using minfi package. The generated p values
were moderated using the eBayes function in limma
package and corrected for multiple testing using Benja-
mini and Hochberg method as the default method
implemented in the limma package. Probes with a cor-
rected p value < 0.01 and a methylation difference
greater than 10% were considered significant. The iden-
tified signature was examined using unsupervised hier-
archical clustering to determine its ability in separating
the patients from controls.
Identification of the differentially methylated regions
(DMRs)
To find genomic regions harboring methylation changes,
a bump hunting approach was used by the bumphunter
package [20]. The analysis considered regions with
greater than 10% change in the overall methylation be-
tween cases and controls with gaps no more than 500
base pairs among neighboring CpGs. The 10% methyla-
tion cutoff was chosen to avoid reporting of methylation
patterns with low-effect size or those influenced by vari-
ability in microarray technology. As suggested by the
package, a 1000 bootstrapping procedure was performed
to compute the family-wise error rate (FWER). We se-
lected regions containing a minimum of three consecu-
tive probes and FWER < 0.01. The identified regions
were mapped to CpG islands and coding genes. Gviz
package was used for visualization of the identified
regions.
Constructing and validating a classification model for
Claes-Jensen syndrome
The identified signature was used to build a classification
model for Claes-Jensen syndrome. Caret package [21] was
used for feature selection from the signature. First, a
receiver’s operating characteristic curve analysis was
performed to identify the most differentiating probes.
Those probes with full differentiation between cases and
controls (area under the curve = 1.00) were retained. Next,
pairwise correlations among the remaining probes were
measured to identify and exclude the redundant signals
with R-squared cutoff > 0.8. A multi-class support vector
machine (SVM) with radial basis function kernel was
trained on the remaining probes using e1071 package. To
determine the best hyperparameters and to measure the
accuracy of the model, a tenfold cross-validation was per-
formed. In this process, the training set was divided into
tenfolds. Ninefolds were used for training the model and
onefold for testing. After repeating this iteration for of all
of the tenfolds, the mean accuracy was calculated and the
hyperparameters with the optimal performance were se-
lected. For every sample, the model was set to generate
three classification scores between 0 and 1 as the probabil-
ity of having a methylation profile related to full epi-
signature as seen in affected patients, partial signature as
seen in healthy carriers, and normal methylation profile as
seen in controls. To assess the sensitivity of the model, the
testing cohort, which was not used for identification of the
signature or construction of the SVM, was supplied to the
model. To determine the specificity, we supplied all of
the healthy subjects, which were not used in the earlier
stages of the study, to the model. We complemented
this healthy cohort with a cohort of methylation data-
base from healthy subjects downloaded from GEO (ac-
cession ID: GSE97362). To understand whether the
signature of KDM5C mutation is sensitive to other
medical conditions representing developmental delay
and intellectual disabilities, we tested a group of pa-
tients with a confirmed clinical and molecular diagnosis
of various diseases of such kind using the constructed
model including patients with autism spectrum disorders,
imprinting defect disorders, RASopathies, chromosomal
aberrations, and Down syndrome. As well, it was tested
whether this classifier is sensitive to other diseases of
epigenomic machinery including ones with published
epi-signatures. These included patients with DNMT1-
associated autosomal dominant cerebellar ataxia, deafness,
and narcolepsy, ATRX, and Floating-Harbor syndrome,
collected from the Children’s Hospital of Eastern Ontario,
and samples from patients with Saethre-Chotzen Syn-
drome, Coffin-Siris syndrome, Coffin-Lowry syndrome,
Rett syndrome, Kabuki syndrome, and CHARGE syn-
drome, collected from the Greenwood Genetic Center.
The same methylation array procedures as described
earlier were conducted for them. The CHARGE and
Kabuki cohorts were supplemented by methylation array
files publically available from GEO (GSE97362). Files from
patients with Sotos and Weaver syndromes were also
downloaded from GEO (GSE74432) and added to this
testing cohort.
Results
Description of the study cohort
The discovery cohort was composed of seven male
patients affected with Claes-Jensen syndrome (mean age
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± SD 21.2 ± 14.3). A group of 56 healthy male individuals
(mean age ± SD 19.3 ± 12.2) from our reference cohort
were matched with the patients for identification of the
epi-signature. The training cohort, which was used for
development of a classification model, was composed of
the discovery cohort in addition to six healthy female
carriers of the KDM5C mutations. The testing cohort,
which was only used to measure the performance of the
classification model, is composed of three affected male
patients and two healthy female carriers. Table 1 shows
the demographic and molecular characteristics of all of
these subjects. Figure 1 shows a schematic representa-
tion of the overall study cohort.
Epigenomic profiling of KDM5C mutation
From a total of 427,492 CpG probes in the Illumina Infi-
nium methylation 450k array that passed the quality
assessment, 1769 probes were found to have > 10% methy-
lation difference between the affected male patients and
controls with multiple testing corrected p value < 0.01
(equal to a nominal p value < ~0.00000001), adjusted for
blood cell type compositions using limma regression
modeling (Additional file 1: Table S1). Unsupervised
hierarchical clustering generated by using these probes
revealed a unique methylation profile, completely sep-
arating the patients from controls. Most of these probes
were hypomethylated in the patients relative to the
controls (1271 hypomethylated vs. 498 hypermethy-
lated, Additional file 1: Table S1, Figure S1), and the
majority (n = 1395) were located inside or nearby a CpG is-
land. Also, a large proportion was located inside or nearby
coding genes, a significant number of which contained
multiple significant probes (Additional file 1: Table S1).
Mapping of differentially methylated genomic regions
(DMRs)
Using a “bump hunting” approach, we identified nine
genomic coordinates containing a minimum of three
CpG probes, an average regional methylation difference
> 0.10, and a family-wise error rate (FWER) < 0.01
(Table 2). The vast majority of these regions overlap
protein-coding genes, and all are found to be located on
or in the vicinity of a CpG island. Except for a ~ 1.2-kb
region on chromosome 15, all of the identified segments
are hypomethylated in patients relative to controls. This
segment is annotated to the first intron of MIR9-3HG
and is the longest and one of the most differentially
methylated regions identified in this study.
Evaluation of healthy female carriers with KDM5C
mutations using the epi-signature
When healthy female carriers were added to the hier-
archical clustering using the identified epi-signature of
the patients, they did not group with either of the con-
trols or the patients; rather, they represented an inter-
mediate methylation pattern, residing them in between
the two (Fig. 2a). A similar pattern was observed using
the principal component analysis (Fig. 2b). Evaluation of
the DMRs suggested a similar scenario, where the
healthy mutation carriers showed an intermediate level
of methylation as compared with the patients and con-
trols for all of the identified regions (Fig. 3). These ob-
servations suggested that the epi-signature of the Claes-
Jensen syndrome can be used for detection of both af-
fected patients and healthy mutation carriers since it
represents a specific pattern in each of these situations.
Development and validation of a classification model for
patients and carriers
To develop a classification model with the capacity of
detecting both patients and carriers, a multi-class sup-
port vector machine (SVM) with radial basis function
kernel was trained using a subset of 198 most differenti-
ating and non-redundant probes selected from the epi-
signature of Claes-Jensen syndrome (Additional file 1:
Tables S2). The training was performed on the training
Table 2 Regions differentially methylated in Claes-Jensen syndrome
Chromosome Start End Width (bps) Methylation difference Probe count FWER Overlapping gene Distance to CpG island
chr15 89,919,993 89,921,182 1190 + 0.28 8 0.001 MIR9-3HG 0
chr17 7,486,551 7,486,874 324 − 0.29 7 0.001 MPDU1 (1121)a 0
chr6 164,092,410 164,093,099 690 − 0.32 6 0.001 0
chr13 113,242,878 113,243,141 264 − 0.33 3 0.004 TUBGCP3 (396) a 221
chr2 25,383,404 25,384,809 1406 − 0.26 7 0.005 POMC 0
chr5 176,559,334 176,559,563 230 − 0.33 3 0.005 NSD1 (1270) a 0
chr2 232,348,334 232,348,794 461 − 0.28 4 0.008 0
chr1 7,887,199 7,887,560 362 − 0.24 5 0.009 PER3 0
chr16 2,801,793 2,801,952 160 − 0.31 3 0.01 SRRM2-AS1 0
Methylation difference is calculated by subtracting average regional methylation levels in controls from the patients (patients − controls)
FWER family-wise error rate, bps base pairs
aDistance in base pair from the transcription start site
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cohort composed of 7 patients, 6 female carriers, and 56
controls. For every given subject, the model was set to
generate three classification scores between 0 and 1 as
the probability of having a methylation profile similar to
those seen in patients, healthy carriers, and controls. A
tenfold cross-validation of this model revealed an accur-
acy of 100%, and it correctly predicted the class of all of
the subjects that were used for its training (Fig. 4).
Next, to determine the predictive power of this model
on samples which were not used for its training, we sup-
plied the model with the testing cohort (three patients
and two carriers). These subjects were not used for the
identification of the epi-signature or construction of the
model. All of these samples received high scores for the
correct class which they belonged to and low scores for
the other two categories (Fig. 4). To estimate the specifi-
city of our method, we used 469 healthy controls from
our reference cohort that were not used earlier in this
study. As well, we downloaded the methylation data
from a set of 125 healthy subjects available publically
from GEO (accession ID GSE97362). All of these sam-
ples received very low scores by our model for having a
methylation profile as seen in either of the patients or
the carriers (Fig. 4), suggesting that this model is 100%
specific to the methylation profile of KDM5C mutation
using these two large confirmation datasets.
The classification model for Claes-Jensen syndrome is not
sensitive to other diseases of epigenomic machinery or
other DD/ID conditions
To determine whether this model can distinguish the epige-
nomic profile of KDM5C mutation from other syndromes
resulting from the defects in epigenomic machinery, we
supplied the model with a cohort of 275 samples, com-
posed of patients with both clinical and molecular diagno-
ses of ATRX syndrome (n = 19), Floating-Harbor syndrome
(n = 17), CHARGE syndrome (n = 83), DNMT1-associated
autosomal dominant cerebellar ataxia, deafness, and
Fig. 2 Clustering of the patients, carriers, and controls using the epi-signature: a unsupervised hierarchical clustering of patients, carriers, and
normal controls shows two distinct clusters for patients (blue bar), and controls (red bar), and an intermediate cluster for the carriers (green bar).
The rows represent the individual probes, and the columns represent the individual samples. Dark blue represents hypermethylation, and light
blue represents hypomethylation in patients relative to the controls. b The first two components of the principal component analysis of patients
(blue), carriers (green), and controls (red), based on the methylation status of the probes in the epi-signature, show a complete separation of
patients from controls, while the carriers are placed in between the two
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narcolepsy (n = 5), Sotos syndrome (n = 38), Coffin-Lowry
syndrome (n = 11), Coffin-Siris syndrome (n = 9), Kabuki
syndrome (n = 44), Weaver syndrome (n = 7), Saethre-
Chotzen syndrome (n = 25), and Rett syndrome (n = 17).
All of these patients received low scores for having methy-
lation profiles similar to those generated by KDM5C
mutations (Fig. 4). Next, to determine the performance
of this classifier in patients with developmental delay/
intellectual disability (DD/ID) of other etiologies, the
model was supplied with the methylation profile of 146
patients with autism spectrum disorders, 12 patients
with various chromosomal abnormalities, 7 patients
with Down syndrome, 50 patients with imprinting con-
ditions (Angelman, Beckwith-Wiedemann, Prader-Willi
syndrome), and 97 patients with various forms of
RASopathies. All of these subjects had a confirmed
clinical and molecular diagnosis of the mentioned con-
ditions. Similar to the previous observations, all of
these patients received low scores for the disease and
carrier categories in our classification model, further
suggesting that the epi-signature of KDM5C mutation
is highly specific to Claes-Jensen type of intellectual
disability (Fig. 4).
Discussion
This study described a genome-wide DNA methylation
signature specific to patients with Claes-Jensen syn-
drome, resulting from pathogenic mutations in KDM5C.
It also demonstrated that a similar but less pronounced
pattern of DNA methylation exists in healthy individuals
who carry these pathogenic mutations. These methyla-
tion patterns seem to be highly specific to Claes-Jensen
syndrome and not be sensitive to other diseases that re-
sult from the disruption of the epigenomic machinery or
other conditions that present with DD/ID. These find-
ings are consistent with the emerging evidence that
unique germline DNA methylation patterns can be
found where the epigenomic machinery is disrupted.
This will have a direct clinical application in disease
screening and differential diagnosis of Claes-Jensen
syndrome.
Fig. 3 Hypomethylation of chr17:7486551-7486874: This segment is annotated to the promoter of MPDU1, which with an average hypomethylation
of 29%, is one of the most differentially methylated regions between the patients (pink) and controls (blue). The inclusion of healthy carriers (green)
generates a methylation pattern between the two groups. Track 1, chromosome ideogram; track 2, CpG probes; track 3, gene region; track 4,
methylation level data; line, average methylation; shadow, 95% confidence interval; dots, methylation values from every single sample (0–1)
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The first published study to examine the DNA methy-
lation changes in patients with Claes-Jensen syndrome
was conducted by Grafodatskaya et al. [22] using
HumanMethylation 27 BeadChip array, where the au-
thors revealed recurrent global DNA hypomethylation
changes in the peripheral blood sample of affected male
individuals. The main limitation of that study was the
use of a small cohort of controls and a low-resolution
microarray platform (27,000 probes vs. 450,000 probes).
Given the limited overlap of the probe sets between
these two microarray technologies (< 5%), it is not pos-
sible to make a direct comparison between the findings
of the two studies. However, both studies show a distinct
pattern of DNA methylation in Claes-Jensen patients
with KDM5C mutations, mainly composed of hypo-
methylated regions, as compared with the controls. This
hypomethylation is most likely related to the loss of ly-
sine demethylase activity of Kdm5c, which has been
shown to be required for the maintenance of global
DNA methylation [23]. However, the smaller degree of
hypermethylation changes observed in this study might
suggest that the consequence of the Kdm5c function loss
is beyond its immediate targets, and the cascade of
events that happen following its disruption may lead to
a downstream imbalance in the regulation of many
genes and genomic features.
Claes-Jensen syndrome is not the only condition
caused by mutations in genes that are involved in regu-
lating epigenetic machinery and chromatin regulation.
More than 50 such disorders have been reported. One of
the common clinical findings of these disorders is vari-
able degrees of intellectual disability. The exact molecu-
lar mechanism involved in the pathophysiology of these
disorders has not been well established. Accumulating
evidence suggests that mutations affecting the function
of these genes can result in altered epigenomic and tran-
scriptional regulation of a large number of genes in the
downstream pathways, which could eventually lead to
the emergence of a variety of clinical features associated
with these conditions. In line with this theory, our
Fig. 4 Probability scores generated by the classification model: A multi-class SVM classifier concurrently generates two scores for every subject as
the probability of having a DNA methylation profile similar to patients with Claes-Jensen syndrome (a) and healthy carriers of KDM5C mutations
(b). y-axis represents scores 0–1, with higher scores indicating a higher chance of carrying a methylation profile related to any of the two statuses.
The x-axis represents the classification scores for 10 patients with Claes-Jensen syndrome, 8 healthy carriers of KDM5C mutations, a total of 650
normal controls, and 587 patients with other conditions that present with intellectual disability as described in the “Methods” and “Results” sections. By
default, the SVM classifier defines a cutoff of 0.5 for predicting the class; however, the vast majority of the tested individuals received a score close to 0
or 1. Therefore, for the purpose of better visualization, the points are jittered. Every point represents the probability score received for a single sample.
This figure represents scores obtained by both the subjects in the training and testing cohorts
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previous studies have identified specific epigenetic signa-
tures for several disorders, including X-linked mental re-
tardation with α-thalassemia, Floating-Harbor syndrome,
DNMT1-associated cerebellar ataxia, deafness, and nar-
colepsy syndrome, as well as Kabuki syndrome [8–12].
These disorders are all caused by loss of function muta-
tions in different genes involved in epigenomic machin-
ery. Similarly, a unique methylation epi-signature has
been reported for Sotos syndrome, caused by mutations
in the NSD1 gene, which encodes histone H3 lysine 36
methyltransferase [13]. Of interest, we also found a
hypomethylated region in the promoter of the NSD1
gene (mutations of which lead to Sotos syndrome) in pa-
tients with Claes-Jensen syndrome. This suggests that
elucidation of the involved biological mechanisms will
require a comprehensive pathway and system analysis. It
is likely that a variety of shared pathways and gene net-
works, potentially in a hierarchical order, are mutually
altered across many of these conditions. This raises the
question whether the DNA methylation epi-signature of
the KDM5C mutations is similar to other diseases that
result from the defects in histone modifications, specific-
ally dysregulation of H3K4 residue marks. We tried to
answer this question by supplying a large cohort of such
diseases, including 44 patients with Kabuki syndrome
that results from mutations in KMT2D (another regula-
tor of the H3K4) to our classification model for KDM5C
epi-signature. All of these subjects received low scores
for having a DNA methylation profile similar to the car-
riers or patients, suggesting that although the initial
event might involve overlapping targets in the large net-
work of histone modifier proteins, the downstream
changes are unique to every condition.
A fascinating feature of Claes-Jensen syndrome is
while the clinical consequence of Kdm5c disruption in
humans is mainly neuropsychological, the biological fea-
tures of Kdm5c function loss can be present in all cells.
The disease is caused by germline mutations, and spe-
cific gene expression patterns have been observed in the
peripheral blood of the affected individuals [24]. This
suggests that changes in the DNA methylation, similar
to gene expression changes, can be observed in multiple
tissues without presenting a phenotype. If the disease
DNA methylation pattern is established early in the de-
velopment, it can be maintained by DNMT1 in multiple
lineages including the peripheral blood [14]. This is con-
sistent with our observation that the KDM5C mutations
generated a specific DNA methylation profile in the per-
ipheral blood of the patients and carriers, completely
distinct from what can be observed in healthy individ-
uals or those affected by other forms of DD/ID. Al-
though it is not clear to what extent the changes that we
observed in this study represent the defective biological
processes that occur in the nervous system of the
patients with this form of intellectual disability, they will
have a great potential for clinical screening and molecu-
lar diagnosis.
The clinical diagnosis of Claes-Jensen syndrome is
challenging by the fact that KDM5C mutations are re-
sponsible for only 1–4% of all types of X-linked inherited
intellectual disabilities. The differential diagnosis is fur-
ther complicated by the overlapping clinical features of
this syndrome with the numerous DD/ID disorders that
present with intellectual disability. In addition, the clin-
ical phenotype associated with mutations in the KDM5C
gene shows a degree of variability with regard to the fa-
cial dysmorphism and cognitive impairment [25], mak-
ing the diagnosis difficult by merely relying on the
clinical findings. Similarly, sequence variant screening
does not always provide a definitive answer. Routine
clinical molecular diagnosis is performed on exons and
exon-intron boundaries, and variants in non-coding re-
gions are not often screened (e.g., promoter, intron).
Within coding regions, missense and in-frame indels are
not easily interpreted and are most often classified as
variants of unknown clinical significance (VUS). Classifi-
cation and interpretation of such variants are a challenge
in molecular diagnostics and genetic counseling, despite
the fact that they can induce protein truncation through
altering the protein synthesis, stability, post-translational
modification, and interaction with other proteins, or in-
duce haploinsufficiency through a dominant-negative ef-
fect [26]. As an example in this study cohort, without
RNA analysis [17], it would not have been possible to es-
tablish a pathogenic status for the c.1583+5G>A variant
that was found in patient cms4919B (Table 1). Our clas-
sification model based on DNA methylation that is pre-
sented in this study has an optimal performance in
detecting both patients with Claes-Jensen syndrome and
healthy carriers with pathogenic variants in KDM5C.
Using multiple large cohorts of healthy control subjects
and patients with various forms of DD/ID conditions,
we demonstrated that this model is highly specific to the
methylation profile generated by KDM5C mutations.
This can be used as a clinical test for resolving the cases
where sequence variant assessment alone could not pro-
vide a definitive answer. This method is particularly
under development in other diseases that result from
the disruption of epigenomic machinery [8–13].
While KDM5C sequencing remains the standard
approach for molecular assessment of patients with
suspected Claes-Jensen syndrome, a genomic DNA
methylation analysis may be used to augment this ap-
proach. In particular, DNA methylation profiling can be
useful for reclassification of VUSs that are commonly
detected by sequencing in clinical laboratories. An alter-
native, broader approach may involve routine genomic
DNA methylation screening of patients with a broad
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range of developmental disorders for which known DNA
methylation defects are identified such as conditions due
to imprinting defects (Prader-Willi, Angelman, Beckwith-
Weidman, Silver-Russell syndromes), uniparental disomy,
Fragile X syndrome, and disorders with known peripheral
blood epi-signatures [14, 27]. Given the technical cost of
this array-based approach is similar to the cost of an aver-
age single-gene molecular test, genomic DNA methylation
profiling may have a potential to be applied as an initial
screen to augment current genomic screening tests in-
cluding CNV microarray testing and exome sequencing.
Conclusion
In conclusion, this study reports a specific methylation
“epi-signature” resulting from loss of function mutations
in the KDM5C gene that can be used to diagnose males
with X-linked intellectual disability and asymptomatic
female carriers. Our highly specific classification model
that is presented here for this condition will potentially
have a direct application for the screening of patients
with overlapping characteristics with Claes-Jensen syn-
drome and may help classify variants of the unknown
clinical significance in the KDM5C gene. This unique
DNA methylation epi-signature along with peripheral
blood epi-signatures from other genetic conditions, im-
printing disorders [28], Fragile X syndrome [29], and
other diseases that remain to be discovered, provides an
avenue for the implementation of genomic DNA methy-
lation screening for routine clinical testing of patients
with a broad range of hereditary developmental and/or
intellectual disability disorders. Our classification algo-
rithm using 198 CpGs can be used as a cost-effective
targeted assay for screening of subjects suspected to
have Claes-Jensen syndrome, for whom the sequence
variant analysis is not conclusive. Alternatively, these
subjects can be screened using a genome-wide approach
if other epigenetic abnormalities are suspected or differ-
ential diagnosis is not possible merely based on clinical
findings.
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